Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice.

ABSTRACT: Few effective therapeutic options are currently available for the treatment of non-small cell lung cancer (NSCLC) with brain metastases (BM). Recent evidence shows that NSCLC patients with BMs respond well to afatinib, but little is known about the underlying mechanisms. In this study, we evaluated the efficacy of afatinib in treatment of BMs in mice and investigated whether afatinib could actively penetrate the brain-blood barrier and bind to its target. NSCLC BM model was established in nude mice by intracerebral injection of PC-9.luc cells. The tumors were measured weekly using in vivo quantitative bioluminescence. The mice are administrated afatinib (15, 30 mg·kg^-1·d^-1, ig) for 14 d. The antitumor efficacy of afatinib was determined by tumor growth inhibition (TGI

SUBMITTER: Zhang SR 

PROVIDER: S-EPMC5309749 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature